- Home
- HE vs AUPH Comparison
HE vs AUPH Comparison
Compare HE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HE | AUPH |
|---|---|---|
| Founded | 1891 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HE | AUPH |
|---|---|---|
| Price | $12.69 | $15.16 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $13.25 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 106.32 | ★ 5075.00 |
| EPS | 0.18 | ★ 0.25 |
| Revenue | ★ $3,086,896,000.00 | $283,055,000.00 |
| Revenue This Year | $7.00 | $17.54 |
| Revenue Next Year | $4.06 | $15.74 |
| P/E Ratio | $70.89 | ★ $59.72 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $10.60 | $10.34 |
| 52 Week High | $17.33 | $19.25 |
Technical Indicators
Market Signals| Indicator | HE | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 34.02 | 43.82 |
| Support Level | $11.03 | $14.60 |
| Resistance Level | $12.69 | $15.23 |
| Average True Range (ATR) | 0.29 | 0.49 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 3.50 | 38.43 |
Price Performance
Historical ComparisonAbout HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.